靶向实验性脓毒症与内毒素血症中的毛细血管渗漏:动物研究中治疗药物、方法与模型的系统评价
啮齿类占81.2%,LPS内毒素血症模型占59.7%,染料法为啮齿类最常用渗漏读出(81.7%),肺为最常评估器官。93.1%研究报告至少一项渗漏结局获益,提示显著发表偏倚;232种不同干预中仅少数在2015年后有随机临床试验评估,尚无毛细血管渗漏特异性疗法达到高转化优先级。作者建议标准化渗漏评估、更多活病原大动物模型、后处理给药范式和富集内皮功能障碍的临床试验。
要点
- 93.1%研究报告至少一项毛细血管渗漏结局获益,提示显著发表偏倚,临床转化需谨慎解读阳性结果。
- 232种不同干预中仅少数在2015年后有随机临床试验评估,尚无毛细血管渗漏特异性疗法达到高转化优先级。
- 肺为最常评估器官;内皮活化(12.2%)、细胞间连接(11.2%)、NO通路(8.9%)为最常靶向通路。
- 缩小转化差距需标准化渗漏评估、活病原大动物模型、后处理给药范式及富集内皮功能障碍的临床试验。
适用人群与场景
- 实验性脓毒症与内毒素血症动物模型(在体研究),非人类临床人群;啮齿类占81.2%,大动物研究以液体平衡和淋巴/血浆比值为主要渗漏读出。
- 纳入标准为在体实验性脓毒症或内毒素血症中评估靶向毛细血管渗漏的干预措施;排除标准原文未提及。
诊断标准与关键阈值
- 毛细血管渗漏评估方法:啮齿类最常用染料法(81.7%),大动物以液体平衡和淋巴/血浆比值为主要读出;肺为最常评估器官。
- 偏倚风险评估使用SYRCLE工具;转化质量采用四标准评分(可重复性、模型质量、临床相关时机、多模态读出)。
- 系统评价注册号PROSPERO CRD42024522372。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 93.1%研究报告干预对至少一项毛细血管渗漏结局有益,提示显著发表偏倚;232种不同干预中仅少数在2015年后有随机临床试验评估。
- 无毛细血管渗漏特异性疗法达到高转化优先级;肺为最常评估器官,内皮活化(12.2%)、细胞间连接(11.2%)、NO通路(8.9%)为最常靶向通路。
证据类型、等级与局限
- 局限:动物模型与结局异质性大、过度依赖LPS内毒素血症模型(59.7%)、93.1%研究报告获益提示发表偏倚、仅少数干预有2015年后随机临床试验评估。
对床旁实践的改变
- 提示急诊/ICU医生:临床前脓毒症毛细血管渗漏干预的阳性结果多来自异质性大、偏倚风险高的动物研究,不能直接外推为临床推荐。
- 尚无毛细血管渗漏特异性疗法达到高转化优先级,临床不应基于此系统评价改变现有脓毒症渗漏管理实践。
- 未来方向:标准化渗漏评估、活病原大动物模型、后处理给药范式和富集内皮功能障碍的临床试验。
指南或共识出处
- 原文未提及指南或共识;系统评价注册号PROSPERO CRD42024522372。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis-induced capillary leak is a major contributor to circulatory dysfunction and tissue edema, yet remains therapeutically unaddressed: numerous interventions showing promise in preclinical models have failed to demonstrate clinical efficacy. This systematic review aimed to characterise preclinical studies evaluating therapeutic interventions specifically targeting capillary leak and to identify candidates with the highest potential for clinical translation.
METHODS: A systematic search of PubMed, Embase, and Web of Science identified in vivo studies in experimental sepsis and endotoxemia evaluating interventions targeting capillary leak. Data on animal models, sepsis induction methods, capillary leak assessment, therapeutic targets, and intervention timing were extracted. Risk of bias was assessed using the SYRCLE tool. As a complementary step, all retained interventions were cross-referenced against randomized or prospective clinical studies in sepsis published since January 2015 and appraised using a four-criterion translational quality score (reproducibility, quality of the model, clinically relevant timing, and multimodal read-out).
RESULTS: Three hundred and three preclinical studies were included, exhibiting substantial heterogeneity in both models and outcomes. Rodent models predominated (81.2%), and lipopolysaccharide-induced endotoxemia was the most common induction method (59.7%). Dye-based assays constituted the most frequent capillary leak read-out in rodents (81.7%), whereas fluid balance and lymph-to-plasma ratios predominated in large-animal studies. The lung was the most frequently evaluated organ. Endothelial activation (12.2%), intercellular junctions (11.2%), and the nitric oxide pathway (8.9%) were the most targeted pathways. A beneficial effect of the intervention on at least one capillary leak outcome results was reported in 93.1% of studies, raising substantial concerns regarding publication bias. Of 232 distinct interventions, only a minority had been evaluated in randomized clinical trials since 2015, and no capillary leak-specific therapy has yet reached high translational priority.
CONCLUSIONS: Preclinical research on sepsis-induced capillary leak is characterized by methodological heterogeneity, a disproportionately high rate of studies reporting capillary leak reduction, and an overreliance on endotoxemia models. Bridging the translational gap will require standardized assessment of capillary leak, broader use of live-pathogen large-animal models, post-treatment dosing paradigms, and clinical trials enriched for endothelial dysfunction.
REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO) number CRD42024522372.
参考来源
- Dumargne H, Hong Ly S, Louzier V, et al. Targeting capillary leak in experimental sepsis and endotoxemia: a systematic review of therapeutic agents, methods and models in animal studies. Crit Care. 2026. PMID: 42827248. doi:10.1186/s13054-026-06160-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。